Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.Advances in experimental medicine and biology · 2021
   Review
2. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.Kidney international supplements · 2018
   Article
3. Reduced impact of renal failure on the outcome of patients with alcoholic liver disease undergoing liver transplantation.Liver international : official journal of the International Association for the Study of the Liver · 2017
   Article
4. Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy.Journal of clinical and translational hepatology · 2016
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as